Patents Assigned to Schwarz Pharma AG
  • Publication number: 20100324144
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.
    Type: Application
    Filed: June 29, 2007
    Publication date: December 23, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventors: Cara Heers, Thomas Stoehr, Bettina Beyreuther
  • Publication number: 20100273714
    Abstract: The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.
    Type: Application
    Filed: June 15, 2007
    Publication date: October 28, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventor: Thomas Stoehr
  • Publication number: 20100130606
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 27, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-J├╝rgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20100099770
    Abstract: The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.
    Type: Application
    Filed: December 21, 2009
    Publication date: April 22, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventor: Norma Selve
  • Patent number: 7687553
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: March 30, 2010
    Assignee: Schwarz Pharma AG
    Inventors: Bettina Beyreuther, Thomas Stohr
  • Patent number: 7670621
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Grant
    Filed: April 3, 2004
    Date of Patent: March 2, 2010
    Assignee: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20100029543
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.
    Type: Application
    Filed: October 12, 2009
    Publication date: February 4, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventors: Bettina Beyreuther, Thomas Stohr
  • Patent number: 7632859
    Abstract: By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: December 15, 2009
    Assignee: Schwarz Pharma AG
    Inventors: Gai Ling Li, Johanna Aaltje Bouwstra, Hans-Michael Wolff, Akhmad Karis Nugroho
  • Publication number: 20090274761
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 5, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Armin BREITENBACH, Claus MEESE, Hans-Michael WOLFF, Roland DREWS
  • Publication number: 20090192224
    Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
    Type: Application
    Filed: June 6, 2007
    Publication date: July 30, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventor: Claus Meese
  • Publication number: 20090117159
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: December 23, 2008
    Publication date: May 7, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-Jurgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20090042981
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Application
    Filed: April 17, 2008
    Publication date: February 12, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Claus Meese, Bengt Sparf
  • Publication number: 20090018198
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies.
    Type: Application
    Filed: September 18, 2008
    Publication date: January 15, 2009
    Applicant: Schwarz Pharma AG
    Inventor: Thomas Stohr
  • Publication number: 20080287545
    Abstract: The present invention is directed to the use of a class of peptide compounds for the prophylaxis and treatment of chronic headache, particularly migraines.
    Type: Application
    Filed: April 15, 2005
    Publication date: November 20, 2008
    Applicant: SCHWARZ PHARMA AG
    Inventors: Dieter Scheller, Thomas Stohr
  • Patent number: 7427601
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating essential tremor and other tremor syndromes.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: September 23, 2008
    Assignee: Schwarz Pharma AG
    Inventor: Thomas Stoehr
  • Publication number: 20080227995
    Abstract: A process of producing a compound of the following formula (3): wherein R1 is a C1-5 alkyl group, R2 is a halogen atom, a C1-5 alkyl group, a C2-5 alkenyl group, a C2-5 alkynyl group, a C1-5 alkyl group, a C1-5 alkoxy group, a nitro group, or a hydroxy group, wherein multiple R2 may be the same or may be different, and a is an integer of from 0 to 4, comprising reacting a compound of the following formula (2): wherein R2 and a are as defined above with a C1-5-alkanesulfonyl chloride or C1-5-alkanesulfonic acid anhydride followed by hydrolyzing an N,N-disulfonated derivative of compound (3) to the compound of formula (3).
    Type: Application
    Filed: July 20, 2006
    Publication date: September 18, 2008
    Applicant: Schwarz Pharma AG
    Inventors: Jorg Hamann, Ralf Kanzler, Youxin Li
  • Patent number: 7416864
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating primary or/and secondary dyskinesias such as tardive dyskinesia.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: August 26, 2008
    Assignee: Schwarz Pharma AG
    Inventor: Thomas Stoehr
  • Publication number: 20080194539
    Abstract: The invention relates to annelated phenyl piperazine and phenyl diazepane carboxamides of general formula (I) containing oxygen. The compounds are suitable for medical use.
    Type: Application
    Filed: December 27, 2005
    Publication date: August 14, 2008
    Applicant: Schwarz Pharma AG
    Inventors: Peter Gmeiner, Harald Hubner, Karin Schlotter
  • Patent number: 7384980
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: June 10, 2008
    Assignee: Schwarz Pharma AG
    Inventors: Claus Meese, Bengt Sparf
  • Publication number: 20080027137
    Abstract: The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the O-methylation of a compound of formula I to produce a compound of formula II in a single step reaction.
    Type: Application
    Filed: September 30, 2005
    Publication date: January 31, 2008
    Applicant: SCHWARZ PHARMA AG
    Inventors: Jens Riedner, Gavin Dunne